Oral estramustine and oral etoposide for hormone-refractory prostate cancer.

  title={Oral estramustine and oral etoposide for hormone-refractory prostate cancer.},
  author={Meletios Athanasios Dimopoulos and Christos Panopoulos and Christina Bamia and Charalambos N Deliveliotis and Gerasimos Alivizatos and Dimitrios Pantazopoulos and Constantinos A. Constantinidis and Athanassios Kostakopoulos and Ioannis Kastriotis and Anastasios Zervas and Gerassimos Aravantinos and Constantin Dimopoulos},
  volume={50 5},
OBJECTIVES Estramustine and etoposide have been shown to inhibit the growth of prostate cancer cells in experimental models. An in vivo synergism of the two agents, when administered to patients with metastatic prostate cancer refractory to hormone therapy, has been reported. To confirm these results, we administered this combination to a large number of patients with hormone-refractory prostate cancer (HRPC). METHODS Fifty-six patients with metastatic HRPC were treated with oral estramustine… CONTINUE READING